AVTX - Avalo Therapeutics

-

$undefined

N/A

(N/A)

Avalo Therapeutics NASDAQ:AVTX Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.

Location: 540 Gaither Rd Ste 400, Maryland, 20850-6713, United States | Website: www.avalotx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-66.17M

Cash

93.43M

Avg Qtr Burn

-8.022M

Short % of Float

8.96%

Insider Ownership

1.76%

Institutional Own.

39.21%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AVTX-803 (CERC-803) Details
Leukocyte Adhesion Deficiency Type II

Phase 3

Data readout

AVTX-009 Details
Hidradenitis suppurativa, Autoimmune disease

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

AVTX-007 (CERC-007) Details
Multiple myeloma, Adult Onset Still's Disease

Phase 1b

Update

Phase 1b

Update

AVTX-801 (CERC-801) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued

AVTX-802 (CERC-802) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued

AVTX-006 (CERC-006) Details
Lymphatic malformations

Failed

Discontinued